Table of Contents
Chromatography Research International
Volume 2011, Article ID 801656, 7 pages
http://dx.doi.org/10.4061/2011/801656
Research Article

Development and Validation of RP-HPLC Method for Quantitative Estimation of Vinpocetine in Pure and Pharmaceutical Dosage Forms

1Department of Pharmacy, Southeast University, Banani, Dhaka 1213, Bangladesh
2Product Development, ACI Limited, Narayanganj 1400, Bangladesh
3Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh

Received 14 June 2011; Revised 16 August 2011; Accepted 29 August 2011

Academic Editor: Esther Turiel

Copyright © 2011 Subrata Bhadra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Z. Szatmari and P. J. Whitehouse, “Vinpocetine for cognitive impairment and dementia,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Bereczki and I. Fekete, “A systematic review of vinpocetine therapy in acute ischaemic stroke,” European Journal of Clinical Pharmacology, vol. 55, no. 5, pp. 349–352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Béla and K. Egon, “On the mechanism of action of vinpocetine,” Acta Pharmaceutica Hungarica, vol. 66, no. 5, pp. 213–224, 1996. View at Google Scholar · View at Scopus
  4. P. Pudleiner and L. Vereczkey, “Study on the absorption of vinpocetine and apovincaminic acid,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 18, no. 4, pp. 317–321, 1993. View at Google Scholar · View at Scopus
  5. T. Szakácz, Z. Veres, and L. Vereczkey, “In vitro-in vivo correlation of the pharmacokinetics of vinpocetine,” Polish Journal of Pharmacology, vol. 53, no. 6, pp. 623–628, 2001. View at Google Scholar · View at Scopus
  6. K. I. Jeon, X. Xu, T. Aizawa et al., “Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 21, pp. 9795–9800, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. E. Medina, “Vinpocetine as a potent antiinflammatory agent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 22, pp. 9921–9922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Sitges, E. Galván, and V. Nekrassov, “Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes,” Neurochemistry International, vol. 46, no. 7, pp. 533–540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Seyahi, A. C. Atalar, and H. K. Ergin, “Tumoral calcinosis: clinical and biochemical aspects of a patient treated with vinpocetine,” European Journal of Internal Medicine, vol. 17, no. 6, pp. 436–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. El-Gindy, S. Emara, M. K. Mesbah, and G. M. Hadad, “Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products,” Farmaco, vol. 60, no. 5, pp. 425–438, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Vatsova, S. Tzvetanov, A. Drenska, J. Goranscheva, and N. Tyutyulkova, “Improved gas chromatographic-mass spectrometric method for the quantitative determination of vinpocetine in human plasma,” Journal of Chromatography B, vol. 702, no. 1-2, pp. 221–226, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. The United States Pharmacopeia, Validation of Compendial Methods, USP, Rockville, Md, USA, 32nd edition, 2009.
  13. International Federation of Pharmaceutical Manufactures & Associations (IFPMA), “Validation of analytical procedures: text and methodology,” in Proceedings of the International Conference on Harmonization (ICH ’96), Methodology Q2(R1), Geneva, Switzerland, 1996.
  14. British Pharmacopoeia, Appendix XII G. Uniformity of Weight (mass), Table 2.9.5.-1, BP, London, UK, 2007.
  15. British Pharmacopoeia, Appendix XII A. Disintegration Test for Tablets and Capsules, Test-A, BP, London, UK, 2007.
  16. British Pharmacopoeia, Appendix XVII G. Friability of Uncoated Tablets, BP, London, UK, 2007.